Citation Impact
Citing Papers
Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning
2006
18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer.
2007
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
1999
Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement
2013
The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers
2007
Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
2010
The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview
2012
Long-term results of the co-operative German–Austrian–Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs
1998
Thyroid cancer
2016 Standout
Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
2013
Current Approaches to Primary Therapy for Papillary and Follicular Thyroid Cancer
2001 Standout
Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study
2001
Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules?
2008
Can 18F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
2011
The Role of MR Imaging in Detecting Nodal Disease in Thyroidectomy Patients with Rising Thyroglobulin Levels
2008
Role of isotope scan, including positron emission tomography/computed tomography, in nodular goitre
2014
Cushing's syndrome
2015 Standout
Phaeochromocytoma
2005 Standout
Head and neck cancer
2008 Standout
Targeted Radiotherapy With Submyeloablative Doses of 131I-MIBG Is Effective for Disease Palliation in Highly Refractory Neuroblastoma
2003
Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET
2005
Cyclical Cushing Syndrome Presenting in Infancy: An Early Form of Primary Pigmented Nodular Adrenocortical Disease, or a New Entity?
2004
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
1993 Standout
131I SPECT/CT in the Follow-up of Differentiated Thyroid Carcinoma: Incremental Value Versus Planar Imaging
2009
Value of FDG PET Imaging in the Management of Patients With Thyroid, Neuroendocrine, and Neural Crest Tumors
2004
Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis
2009
Risk of Malignancy in Nonpalpable Thyroid Nodules: Predictive Value of Ultrasound and Color-Doppler Features
2002 Standout
Utilidad de la 18F-FDG PET/TC en el cáncer de tiroides
2016
Papillary and Follicular Thyroid Carcinoma
1998
A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma
1991
Osteosarcoma treatment – Where do we stand? A state of the art review
2013 Standout
Contribution of technetium-99m hexamethylpropylene amine oxime labelled leucocyte scintigraphy to the diagnosis of diabetic foot infection
1998
18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels
2000
NCCN Task Force: Clinical Utility of PET in a Variety of Tumor Types
2009
Positron emission tomography and positron emission tomography‐CT evaluation for recurrent papillary thyroid carcinoma: Meta‐analysis and literature review
2010
Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer
1997
The Role of Positron Emission Tomography/Computed Tomography in the Management of Recurrent Papillary Thyroid Carcinoma
2005
Expression of the Na+/I−Symporter Gene in Human Thyroid Tumors: A Comparison Study with Other Thyroid-Specific Genes1
1999
Detection of Metastatic Cervical Lymph Nodes in Recurrent Papillary Thyroid Carcinoma
2009
Diagnostic Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Follow-Up of Papillary or Follicular Thyroid Cancer
2001
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium
2006 Standout
Diabetic Foot Disorders: A Clinical Practice Guideline (2006 Revision)
2006 Standout
Neuroblastoma
2007 Standout
Radioiodine Treatment of Thyroid Cancer with the Aid of Recombinant Human Thyrotropin
1998
[18F]Fluorodeoxyglucose Uptake in Recurrent Thyroid Cancer Is Related to Hexokinase I Expression in the Primary Tumor
2005
Detection of Residual and Recurrent Thyroid Cancer by Radionuclide Imaging
1999
Differentiated Thyroid Cancer: Determinants of Disease Progression in Patients <21 Years of Age at Diagnosis
1998
131I MIBG therapy in neuroblastoma: Mechanisms, rationale, and current status
1999
Management of Patients with Scan Negative, Thyroglobulin Positive Differentiated Thyroid Carcinoma
1998
Diagnostic value of serum thyroglobulin measurements in the follow‐up of differentiated thyroid carcinoma, a structured meta‐analysis
2004
Positron emission imaging of head and neck cancer, including thyroid carcinoma
2004
Histological Aggressiveness of Fluorodeoxyglucose Positron-Emission Tomogram (FDG-PET)-Detected Incidental Thyroid Carcinomas
2007
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
2006 Standout
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
2009 Standout
Resistance of [ 18 F]-Fluorodeoxyglucose-Avid Metastatic Thyroid Cancer Lesions to Treatment with High-Dose Radioactive Iodine
2001
Better Yield of 18 Fluorodeoxyglucose-Positron Emission Tomography in Patients with Metastatic Differentiated Thyroid Carcinoma during Thyrotropin Stimulation
2002
Clinical Comparison of Whole-Body Radioiodine Scan and Serum Thyroglobulin After Stimulation with Recombinant Human Thyrotropin
2002
Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management.
2006
Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients
2001
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
123I-Meta-Iodobenzylguanidine Scintigraphy for the Detection of Neuroblastoma and Pheochromocytoma: Results of a Meta-Analysis
2010
[18F]-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography Localizes Residual Thyroid Cancer in Patients with Negative Diagnostic 131I Whole Body Scans and Elevated Serum Thyroglobulin Levels
1999
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
2001
Visually Discernible [18F]Fluorodeoxyglucose Uptake in Papillary Thyroid Microcarcinoma: A Potential New Risk Factor
2010
Prognostic Value of [18F]Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid Cancer
2000
Assessment of the effect of percutaneous ethanol injection in autonomously functioning thyroid nodules by colour-coded duplex sonography
1995
Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors
2013 Standout
Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
2001
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
2002 Standout
Empiric High-Dose 131-Iodine Therapy Lacks Efficacy for Treated Papillary Thyroid Cancer Patients with Detectable Serum Thyroglobulin, but Negative Cervical Sonography and 18F-Fluorodeoxyglucose Positron Emission Tomography Scan
2010
Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease
2012
The determination of the electron density profile of the human erythrocyte ghost membrane by small-angle x-ray diffraction
1977
Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
2001
Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography
2004
Impact of Metaiodobenzylguanidine Scintigraphy on Assessing Response of High-Risk Neuroblastoma to Dose-Intensive Induction Chemotherapy
2003
Redifferentiation therapy-induced radioiodine uptake in thyroid cancer.
1998
American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules - 2016 Update Appendix
2016 Standout
Approach to the Patient with a Positive Serum Thyroglobulin and a Negative Radioiodine Scan after Initial Therapy for Differentiated Thyroid Cancer
2008
18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.
2002
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Guidelines for the management of thyroid cancer
2014 Standout
Analysis of the irregular planar distribution of proteins in membranes
1985 StandoutNobel
Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
2008
PET/CT Imaging of Thyroid Cancer
2011
Thyroid carcinoma
2003 Standout
Lung Metastases From Thyroid Cancer
2007
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
2002 Standout
Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline
2014 Standout
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of U. Feine being referenced
Treatment of neuroblastoma with metaiodobenzylguanidine: Results and side effects
1987
[131I]-Metaiodobenzylguanidine in the treatment of metastatic neuroblastoma
1989
Nuklearmedizinische Vorhersage des histologischen Tumoransprechens beim Osteosarkom*
1989
Angiodynographie bei umschriebenen Schilddrüsenveränderungen
1989
Metaiodobenzylguanidine (MIBG) labeled with 123I/131I in neuroblastoma diagnosis and follow‐up treatment with a review of the diagnostic results of the international workshop of pediatric oncology held in Rome, september 1986
1987
Infektionsdiagnostik in der Chirurgie des Bewegungsapparates mit der Tc-99m-HMPAO-Leukocytenszintigrafie
1989
Clinical Experiences in the Treatment of Neuroblastoma with131I-Metaiodobenzylguanidine
1986
Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer
1998
Thyroid carcinoma in childhood.
1983
Adreno-corticale noduläre Hyperplasie als Ursache eines Cushing-Syndroms in der Neugeborenenperiode
1991
[18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I].
1995
[Extension of survival time of washed erythrocyte sediments in vivo by using an adequate washing solution].
1972
Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
1996